<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LIDOCAINE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(lye'doe-kane)<br/><span class="topboxtradename">Anestacon, </span><span class="topboxtradename">Dilocaine, </span><span class="topboxtradename">L-Caine, </span><span class="topboxtradename">Lidoderm, </span><span class="topboxtradename">Lida-Mantle, </span><span class="topboxtradename">Lidoject-1, </span><span class="topboxtradename">LidoPen Auto Injector, </span><span class="topboxtradename">Nervocaine, </span><span class="topboxtradename">Octocaine, </span><span class="topboxtradename">Xylocaine, </span><span class="topboxtradename">Xylocard <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic, class ib</span>; <span class="classification">central nervous system agent</span>; <span class="classification">local anesthetic (amide type)</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p><b>Antidysrhythmic</b> 300 mg/3 mL auto-injector; 0.2%, 0.4%, 0.8%, 1%, 2%, 4%, 10%, 20% injections
      </p>
<p><b>Local Anesthetic</b> 0.5%, 1%, 1.5%, 2%, 4%
      </p>
<p><b>Topical</b> 2%, 2.5%, 4%, 5% solution;  2.5%, 5% ointment; 0.5%, 4% cream; 0.5%, 2.5% gel; 0.5%, 10% spray; 2% jelly; 0.5% patch
      </p>
<h1><a name="action">Actions</a></h1>
<p>Similar to those of procainamide and quinidine, but has little effect on myocardial contractility, AV and intraventricular
         conduction, cardiac output, and systolic arterial pressure in equivalent doses. Exerts antiarrhythmic action (Class IB) by
         suppressing automaticity in His-Purkinje system and by elevating electrical stimulation threshold of ventricle during diastole.
         Action as local anesthetic is more prompt, more intense, and longer lasting than that of procaine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Suppresses automaticity in His-Purkinje system and elevates electrical stimulation threshold of ventricle during diastole.
         Prompt, intense, and long-lasting local anesthetic.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Rapid control of ventricular arrhythmias occurring during acute MI, cardiac surgery, and cardiac catheterization and those
         caused by digitalis intoxication. Also as surface and infiltration anesthesia and for nerve block, including caudal and spinal
         block anesthesia and to relieve local discomfort of skin and mucous membranes. Patch for relief of pain associated with post-herpetic
         neuralgia.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Refractory status epilepticus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to amide-type local anesthetics; application or injection of lidocaine anesthetic in presence
         of severe trauma or sepsis, blood dyscrasias, supraventricular arrhythmias, Stokes-Adams syndrome, untreated sinus bradycardia,
         severe degrees of sinoatrial, atrioventricular, and intraventricular heart block. Safe use during pregnancy (category B),
         lactation, or in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver or kidney disease, CHF, marked hypoxia, respiratory depression, hypovolemia, shock; myasthenia gravis; debilitated patients,
         older adults; family history of malignant hyperthermia (fulminant hypermetabolism). Topical use in eyes, over large body areas,
         over prolonged periods, in severe or extensive trauma or skin disorders.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ventricular Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 50100 mg bolus at a rate of 2050 mg/min, may repeat in 5 min, then start infusion of 14 mg/min immediately
               after first bolus <span class="rdroute">IM/SC</span> 200300 mg IM,  may repeat once after 6090 min<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.51 mg/kg bolus dose, then 1050 mcg/kg/min infusion<br/><br/><span class="indicationtitle">Anesthetic Uses</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Infiltration</span> 0.51% solution <span class="rdroute">Nerve Block</span> 12% solution <span class="rdroute">Epidural</span> 12% solution <span class="rdroute">Caudal</span> 11.5% solution <span class="rdroute">Spinal</span> 5% with glucose <span class="rdroute">Saddle Block</span> 1.5% with dextrose <span class="rdroute">Topical</span> 2.55% jelly, ointment, cream, or solution<br/><br/><span class="indicationtitle">Post-Herpetic Neuralgia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply up to 3 patches over intact skin in most painful areas once for up to 12 h per 24 h period<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give in deltoid muscle as preferred site.</li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Do not apply topical lidocaine to large areas of skin or to broken or abraded surfaces. Consult physician about covering area
            with a dressing.
         </li>
<li>Avoid topical preparation contact with eyes.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     						Note: Do not use lidocaine solutions containing preservatives for spinal or epidural (including caudal) block. Use <small>ONLY</small> lidocaine HCl injection without preservatives or epinephrine that is specifically labeled for IV injection or infusion.
                     					
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">IV Infusion:</span>  Use D5W for infusion. For adults, add 1 g to 250 or 500 mL to yield 2 or 4 mg/mL, respectively; for children, add 120 mg to
                  100 m to yield 1.2 mg/mL. Do not use solutions with particulate matter or discoloration. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 50 mg or fraction thereof over 1 min.  <span class="methodtype">IV Infusion:</span> Use microdrip and infusion pump. Rate of flow is usually <img src="../images/special/lesserorequal.gif"/>4 mg/min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Phenytoin,</b>
<b>ampicillin,</b>
<b>cefazolin.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B cholesteryl complex,</b>
<b>phenytoin,</b>
<b>thiopental.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Discard partially used solutions of lidocaine without preservatives.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, dizziness, light-headedness, restlessness, confusion, disorientation, irritability, apprehension, euphoria, wild
      excitement, numbness of lips or tongue and other paresthesias including sensations of heat and cold, chest heaviness, difficulty
      in speaking, <span class="speceff-life">difficulty in breathing or swallowing</span>, muscular twitching, tremors, psychosis. With high doses: <span class="speceff-life">convulsions, respiratory depression and arrest</span>. <span class="typehead">CV:</span> With high doses, hypotension, bradycardia, conduction disorders including heart block, <span class="speceff-life">cardiovascular collapse, cardiac arrest</span>. <span class="typehead">Special Senses:</span> Tinnitus, decreased hearing; blurred or double vision, impaired color perception. <span class="typehead">Skin:</span> Site of topical application may develop erythema, edema. <span class="typehead">GI:</span> Anorexia, nausea, vomiting. <span class="typehead">Body as a Whole:</span>  Excessive perspiration, soreness at IM site, local thrombophlebitis (with prolonged IV infusion), hypersensitivity reactions
      (urticaria, rash, edema, <span class="speceff-life">anaphylactoid reactions</span>). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Increases in <span class="alt">creatine phosphokinase (CPK)</span> level may occur for 48 h after IM dose and may interfere with test for presence of MI.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> Lidocaine patch may increase toxic effects of <b>tocainide,</b>
<b>mexiletine;</b>
<span class="classification">barbiturates</span> decrease lidocaine activity; <b>cimetidine,</b>
<span class="classification">beta blockers</span>, <b>quinidine</b> increase pharmacologic effects of lidocaine; <b>phenytoin</b> increases cardiac depressant effects; <b>procainamide</b> compounds neurologic and cardiac effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Topical application is 3% absorbed through intact skin. <span class="typehead">Onset:</span> 4590 sec IV; 515 min IM; 25 min topical. <span class="typehead">Duration:</span> 1020 min IV; 6090 min IM; 3060 min topical; &gt;100 min injected for anesthesia. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier and placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.52 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Stop infusion immediately if ECG indicates excessive cardiac depression (e.g., prolongation of PR interval or QRS complex
            and the appearance or aggravation of arrhythmias).
         </li>
<li>Monitor BP and ECG constantly; assess respiratory and neurologic status frequently to avoid potential overdosage and toxicity.</li>
<li>Auscultate lungs for basilar rales, especially in patients who tend to metabolize the drug slowly (e.g., CHF, cardiogenic
            shock, hepatic dysfunction).
         </li>
<li>Watch for neurotoxic effects (e.g., drowsiness, dizziness, confusion, paresthesias, visual disturbances, excitement, behavioral
            changes) in patients receiving IV infusions or with high lidocaine blood levels.
         </li>
<li>
            							Note: Lidocaine blood levels of 1.56 mcg/mL are reported to provide "usually effective" antiarrhythmic activity. Blood
            levels greater than 7 mcg/mL are potentially toxic.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Swish and spit out when using lidocaine solution for relief of mouth discomfort; gargle for use in pharynx, may be swallowed
            (as prescribed).
         </li>
<li>Oral topical anesthetics (e.g., Xylocaine Viscous) may interfere with swallowing reflex. Do <small>NOT</small> ingest food within 60 min after drug application; especially pediatric, geriatric, or debilitated patients. Do not chew gum
            while buccal and throat membranes are anesthetized to prevent biting trauma.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>